News

Tencent Invests Big Money in US Cleantech

“TenX has invested in Clarity, a three-year-old company that makes air-pollution monitoring devices which provide hyper-localised and real-time air-quality readings in metropolitan areas. Its…

Cypris Materials, Inc. on LinkedIn: #sustainability #innovation #ecofriendly #color #design #printing

We’re excited to share a game-changing development in payment card design and manufacturing!CPI Card GroupandCypris Materials, Inc.have collaborated to…

Rukaib Rizme on LinkedIn: #startupsuccess #energy #mobility #innovation

Congratulations to Epic Charging for achieving well-deserved recognition as one of the top 100 global energy startups of 2024! We're looking forward to…

There is magic in the discovery of a new type of magnetism

Altermagnets could help make computing more energy efficient

Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA

Plus, news about Outlook Therapeutics and Adicet Bio: Merck and Unnatural Products collaborate: Per the deal, Merck will make an undisclosed upfront payment to the Santa Cruz, CA-based biotech and up to $220 million in milestones. The companies plan to develop macrocyclic therapies for cancer. — Jaimy Lee CG Oncology

GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease | GenEdit

SOUTH SAN FRANCISCO, Calif., January 23, 2024 –GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy®platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The companies will employ GenEdit’s NanoGalaxy platform to discover and develop novel nanoparticles to deliver Genentech’s nucleic acid-based medicines for treatment of autoimmune disease.